Andromeda Biotech Ltd. announced initial results from a pivotal phase III clinical study. The 24-month study was randomized, placebo-controlled, designed to assess the safety and efficacy of DiaPep277®, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with Type 1 Diabetes (T1D). The results from patients who were...Read more
Tag Archives: Phase III
D-Pharm Phase III Stroke Report in Feb.
The next crucial milestone is near for the more than 15-year development of a major new ethical Israeli drug. D-Pharm Ltd., (TASE: DPRM) announced that it will be able to determine in February if initial results for its Phase III stroke drug trial indicate enough evidence of a beneficial effect...Read more